With the revolutionary Randox HDL and LDL clearance method, part of the lipid profile, specificity of testing and accuracy of diagnosis is vastly improved. This has replaced traditional assessment of cardiovascular disease (CVD) risk which frequently provided inaccurate and insufficient information for the clinician, possibly leading to misdiagnosis of the patient.

The lipid profile, a group of tests performed to determine risk of CVD, comprises total cholesterol, triglycerides, high density lipoproteins (HDL) and low density lipoproteins (LDL) cholesterol and additional parameters such as apolipoproteins. LDL cholesterol transports cholesterol to the cells for utilisation and plays a central role in the development of atherosclerotic lesions. It is generally regarded as the most important risk factor for CVD. HDL cholesterol, a negative risk factor, transports cholesterol from the cells to the liver for metabolism and elimination from the body. Regular assessment of these parameters is necessary to establish risk and, if necessary, monitor treatment.

Traditional LDL cholesterol measurement based on the Friedewald equation calculated from three separate assays, requires a fasting patient sample and inaccurately estimates cholesterol in hypertriglyceridaemia resulting in misclassification of up to 50% of patient samples. Direct masking methods are a recent development in HDL cholesterol analysis in which non-HDL molecules are masked initially and then HDL cholesterol is measured. However, these methods underestimate HDL levels in hypertriglyceridaemia. This is due to the fact that in abnormal samples, the composition of the lipoproteins is altered by these high levels of triglycerides and therefore cannot be distinguished during the masking process. Furthermore, these methods show poor agreement with ultracentrifugation employed in gold standard reference laboratories.

The Randox HDL and LDL clearance methods overcome these issues by completely removing the non-HDL/LDL molecules before directly measuring the HDL/LDL cholesterol in the sample. It is highly specific and thus eliminates problems associated with hypertriglyceridaemia. The Randox HDL and LDL clearance methods show excellent correlation with ultracentrifugation highlighting its superior accuracy.

Randox HDL and LDL clearance method kits are liquid, ready to use, automatable assays with a wide measuring range and good stability. Accurate HDL and LDL cholesterol measurement is vital to establish CVD risk, and to determine therapeutic effects. By using Randox direct clearance methods you can be assured of a more accurate diagnosis and confidence in your results.

About Randox

Randox is an international diagnostics company, headquartered in the UK. Randox develop, manufacture and market clinical diagnostic products worldwide. Core products are: Biochip Array Technology; clinical chemistry analysers and reagents; quality controls and EQA; recombinant proteins and antibodies.

Randox Laboratories
Diamond Road
Crumlin
Co. Antrim BT29 4QY
United Kingdom
randox